Needham Reiterates Buy on BioCryst Pharma, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on BioCryst Pharma (NASDAQ:BCRX), maintaining a $12 price target. This reaffirms Needham's positive outlook on the company's stock.
April 10, 2024 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger reiterates a Buy rating on BioCryst Pharma, with a maintained $12 price target, indicating a positive outlook.
The reiteration of a Buy rating and maintenance of a $12 price target by a reputable analyst like Serge Belanger from Needham is a strong positive signal for BioCryst Pharma. It suggests confidence in the company's future performance and potential for stock price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100